Robert Ainscow Sells 8,438 Shares of ASP Isotopes (NASDAQ:ASPI) Stock

ASP Isotopes Inc. (NASDAQ:ASPI) COO Robert Ainscow sold 8,438 shares of ASP Isotopes stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00. Following the sale, the chief operating officer owned 2,281,879 shares in the company, valued at $15,973,153. This represents a 0.37% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Robert Ainscow also recently made the following trade(s):

• On Thursday, April 16th, Robert Ainscow sold 22,500 shares of ASP Isotopes stock. The shares were sold at an average price of $5.21, for a total transaction of $117,225.00.

ASP Isotopes Trading Up 6.5%

ASPI opened at $6.23 on Friday. The firm has a market capitalization of $784.36 million, a P/E ratio of -3.00 and a beta of 3.42. The firm’s 50 day moving average is $5.69 and its 200-day moving average is $5.85. ASP Isotopes Inc. has a 52-week low of $3.92 and a 52-week high of $14.49. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69.

ASP Isotopes (NASDAQ:ASPI) last posted its quarterly earnings data on Wednesday, May 20th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. The company had revenue of $8.36 million for the quarter, compared to analyst estimates of $3.68 million. ASP Isotopes had a negative net margin of 644.40% and a negative return on equity of 112.46%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ASPI. Canaccord Genuity Group reiterated a “buy” rating and set a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday, April 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ASP Isotopes presently has an average rating of “Hold” and a consensus price target of $13.00.

Institutional Trading of ASP Isotopes

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Royal Bank of Canada increased its stake in shares of ASP Isotopes by 18.4% in the first quarter. Royal Bank of Canada now owns 37,954 shares of the company’s stock worth $167,000 after buying an additional 5,906 shares during the last quarter. Empowered Funds LLC increased its stake in shares of ASP Isotopes by 38.2% in the first quarter. Empowered Funds LLC now owns 185,953 shares of the company’s stock worth $822,000 after buying an additional 51,351 shares during the last quarter. Encompass Capital Advisors LLC bought a new stake in shares of ASP Isotopes in the first quarter worth $30,551,000. The Manufacturers Life Insurance Company increased its stake in shares of ASP Isotopes by 8.8% in the first quarter. The Manufacturers Life Insurance Company now owns 30,503 shares of the company’s stock worth $135,000 after buying an additional 2,470 shares during the last quarter. Finally, Broadhurst Jeffrey B bought a new stake in shares of ASP Isotopes in the first quarter worth $44,000. Institutional investors own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.